According to an article released by Optum, recent data shows Hepatitis C medications are positively contributing to specialty drug trend reductions and achieving lasting clinical results.

FDA approved medications for Hepatitis C, such as Sovaldi and Harvoni, started entering the market in 2013, and with great controversy. These medications have been effective, but at a huge cost. The initial price (which has since moderated) of a single course of a typical drug could run $85,000 – 95,000 in just three months.

Are you tired of seeing your benefit costs skyrocket year after year? Frustrated about having little or no control over the cost of healthcare? These frustrations make some employers worry about the future of their benefits package, and thus, their ability to attract and retain the right workers.  

The American Health Care Act (AHCA) revised bill designed to repeal/replace the Affordable Care Act (ACA) passed on the House Floor on May 4, 2017. The revised bill included several amendments from the original bill, including changes to limits on Flexible Spending Account (FSA) contributions, age-ratio limits, coverage for pre-existing conditions and essential health benefits (EHB). The bill is headed to the Senate floor where it will either be amended, or the Senate could start from scratch with their own bill.